CN103002877B - 作为缓解疾病的抗风湿性药（dmard）和抗癌药剂的甲氨蝶呤的持续释放制剂 - Google Patents

作为缓解疾病的抗风湿性药（dmard）和抗癌药剂的甲氨蝶呤的持续释放制剂 Download PDF

Info

Publication number
CN103002877B
CN103002877B CN201180023882.8A CN201180023882A CN103002877B CN 103002877 B CN103002877 B CN 103002877B CN 201180023882 A CN201180023882 A CN 201180023882A CN 103002877 B CN103002877 B CN 103002877B
Authority
CN
China
Prior art keywords
mtx
application according
preparation
days
methotrexate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201180023882.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN103002877A (zh
Inventor
路易·丹尼尔·加西亚
洛伊斯·吉布森
威廉·兰伯特
本杰明李
朱良金
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pacira Pharmaceuticals Inc
Original Assignee
Pacira Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pacira Pharmaceuticals Inc filed Critical Pacira Pharmaceuticals Inc
Publication of CN103002877A publication Critical patent/CN103002877A/zh
Application granted granted Critical
Publication of CN103002877B publication Critical patent/CN103002877B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/25—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids with polyoxyalkylated alcohols, e.g. esters of polyethylene glycol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Neurology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201180023882.8A 2010-05-13 2011-05-12 作为缓解疾病的抗风湿性药（dmard）和抗癌药剂的甲氨蝶呤的持续释放制剂 Active CN103002877B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US33454610P 2010-05-13 2010-05-13
US61/334,546 2010-05-13
US12/914,944 US9770414B2 (en) 2010-05-13 2010-10-28 Sustained release formulation of methotrexate as a disease-modifying antirheumatic drug (DMARD) and an anti-cancer agent
US12/914,944 2010-10-28
PCT/US2011/036328 WO2011143484A1 (en) 2010-05-13 2011-05-12 A sustained release formulation of methotrexate as a disease-modifying antirheumatic drug (dmard) and an anti-cancer agent

Publications (2)

Publication Number Publication Date
CN103002877A CN103002877A (zh) 2013-03-27
CN103002877B true CN103002877B (zh) 2017-07-21

Family

ID=44911988

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201180023882.8A Active CN103002877B (zh) 2010-05-13 2011-05-12 作为缓解疾病的抗风湿性药（dmard）和抗癌药剂的甲氨蝶呤的持续释放制剂

Country Status (6)

Country Link
US (3) US9770414B2 (enExample)
EP (1) EP2568962B1 (enExample)
JP (3) JP5980775B2 (enExample)
CN (1) CN103002877B (enExample)
IL (1) IL222683B (enExample)
WO (1) WO2011143484A1 (enExample)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013257546B2 (en) 2012-05-10 2017-12-14 Painreform Ltd. Depot formulations of a local anesthetic and methods for preparation thereof
KR102176971B1 (ko) 2012-07-05 2020-11-11 타이완 리포좀 캄파니 리미티드 관절염의 치료 방법
WO2015147018A1 (ja) * 2014-03-28 2015-10-01 テルモ株式会社 炎症性自己免疫疾患治療用の注射用水性製剤
WO2015183213A1 (en) * 2014-05-28 2015-12-03 Onko İlaç Sanayi̇ Ve Ti̇caret A. Ş. Pharmaceutical dosage forms containing n-[4-[[(2,4-diamino-6-pteridinyl)methyl] methylamino] benzoyl]-l- glutamic acid and n-[4-[[(2-amino-3,4- dihydro -4-oxo-6- pteridinyl) methyl] methyl amino] benzoyl]-l-glutamic acid
ES2969374T3 (es) 2014-07-30 2024-05-17 Massachusetts Eye & Ear Infirmary Metotrexato para la vitreorretinopatía proliferativa
JP5774190B1 (ja) * 2014-12-12 2015-09-09 ジーンメディカル株式会社 皮下注射用剤及び皮下注射用剤を含有する注射器の製造方法
EP3231433B1 (en) * 2014-12-12 2023-12-27 Motejo. Ltd Agent for hypodermic injection
US10213284B2 (en) 2015-06-30 2019-02-26 Tela Bio, Inc. Corner-lock stitch patterns
WO2017015421A1 (en) 2015-07-21 2017-01-26 Tela Bio, Inc. Compliance control stitching in substrate materials
KR20230161532A (ko) 2015-11-24 2023-11-27 메사추세츠 인스티튜트 오브 테크놀로지 치매를 예방, 경감 및/또는 치료하기 위한 시스템 및 방법
US9820843B2 (en) 2016-04-26 2017-11-21 Tela Bio, Inc. Hernia repair grafts having anti-adhesion barriers
WO2018031980A1 (en) 2016-08-12 2018-02-15 L.E.A.F. Holdings Group Llc Polyglutamated antifolates and uses thereof
EP3496757A4 (en) * 2016-08-12 2020-04-15 L.E.A.F Holdings Group LLC POLYGLUTAMATE ANTIFOLATES AND USES THEREOF.
US20180236098A1 (en) 2016-08-12 2018-08-23 L.E.A.F. Holdings Group Llc Alpha and gamma-d polyglutamated antifolates and uses thereof
WO2018094230A2 (en) 2016-11-17 2018-05-24 Cognito Therapeutics, Inc. Methods and systems for neural stimulation via auditory stimulation
KR102069680B1 (ko) * 2017-03-02 2020-01-23 단디바이오사이언스 주식회사 면역억제인자 제어물질을 포함하는 다중도메인캡슐, 이의 제조방법, 및 이를 포함하는 면역조절 조성물
EP3694464B1 (en) 2017-10-10 2025-12-10 Massachusetts Institute of Technology Systems for preventing, mitigating, and/or treating dementia
JP7416700B2 (ja) 2017-11-14 2024-01-17 ザ スキーペンズ アイ リサーチ インスティチュート インコーポレイテッド 増殖性硝子体網膜症および上皮間葉転換と関連付けられる状態の治療のためのｒｕｎｘ１阻害の方法
CN115475142A (zh) * 2017-11-20 2022-12-16 平顶山学院 一种口服甲氨蝶呤脂质体及其制备方法
CA3090506A1 (en) 2018-02-07 2019-08-15 L.E.A.F. Holdings Group Llc Alpha polyglutamated tetrahydrofolates and uses thereof
US12220431B2 (en) 2018-02-07 2025-02-11 L.E.A.F. Holdings Group Llc Gamma polyglutamated antifolates and uses thereof
EP3749321A4 (en) * 2018-02-07 2022-03-09 L.E.A.F Holdings Group LLC Gamma polyglutamated antifolates and uses thereof
US11730738B2 (en) 2018-02-07 2023-08-22 L.E.A.F. Holdings Group Llc Alpha polyglutamated pralatrexate and uses thereof
US12076402B2 (en) 2018-02-07 2024-09-03 L.E.A.F. Holdings Group Llc Alpha polyglutamated antifolates and uses thereof
WO2019157145A1 (en) * 2018-02-07 2019-08-15 L.E.A.F. Holdings Group Llc Gamma polyglutamated pemetrexed and uses thereof
EP3749317A4 (en) * 2018-02-07 2022-06-22 L.E.A.F Holdings Group LLC PEMETREXED ALPHA-POLYGLUTAMATE AND ASSOCIATED USES
US12246015B2 (en) 2018-02-07 2025-03-11 L.E.A.F. Holdings Group Llc Alpha polyglutamated raltitrexed and uses thereof
US12246019B2 (en) 2018-02-07 2025-03-11 L.E.A.F. Holdings Group Llc Alpha polyglutamated lometrexol and uses thereof
EP3749318A4 (en) 2018-02-07 2022-07-06 L.E.A.F Holdings Group LLC GAMMA-POLYGLUTAMATED RALTITREXED AND ITS USES
JP7491573B2 (ja) * 2018-02-07 2024-05-28 エル．イー．エー．エフ． ホールディングス グループ エルエルシー アルファポリグルタミン酸化メトトレキセートおよびその使用
US12310966B2 (en) 2018-02-07 2025-05-27 L.E.A.F. Holdings Group Llc Alpha polyglutamated aminopterin and uses thereof
WO2019160734A1 (en) 2018-02-14 2019-08-22 L.E.A.F. Holdings Group Llc Gamma polyglutamated lometrexol and uses thereof
EP3752158A4 (en) 2018-02-14 2022-03-09 L.E.A.F Holdings Group LLC GAMMA-POLYGLUTAMATED AMINOPTERINE AND USES THEREOF
CA3090753A1 (en) 2018-02-14 2019-08-22 L.E.A.F. Holdings Group Llc Gamma polyglutamated pralatrexate and uses thereof
WO2019160735A1 (en) * 2018-02-14 2019-08-22 L.E.A.F. Holdings Group Llc Gamma polyglutamated tetrahydrofolates and uses thereof
CA3090989A1 (en) * 2018-02-14 2019-08-22 L.E.A.F. Holdings Group Llc Gamma polyglutamated methotrexate and uses thereof
WO2019173792A1 (en) 2018-03-09 2019-09-12 Tela Bio, Inc. Surgical repair graft
EP4585235A3 (en) 2019-03-08 2025-08-20 Tela Bio, Inc. Textured medical textiles
CN110269939A (zh) * 2019-03-12 2019-09-24 武汉愔紫生物科技有限公司 一种治疗真菌分泌蛋白介导的炎症疾病标志物的药物、药物组合物、用途及其使用方法
WO2021216957A1 (en) * 2020-04-23 2021-10-28 Massachusetts Institute Of Technology Systems, devices, and methods for gamma entrainment using sensory stimuli to alleviate cognitive deficits and/or neuroinflammation induced by chemotherapy agents
CN114249731B (zh) * 2020-09-24 2023-09-29 南京海润医药有限公司 一种甲氨蝶呤中间体的精制方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5723147A (en) * 1987-02-23 1998-03-03 Depotech Corporation Multivesicular liposomes having a biologically active substance encapsulated therein in the presence of a hydrochloride
US5759573A (en) * 1993-04-22 1998-06-02 Depotech Corporation Cyclodextrin liposomes encapsulating pharmacologic compounds and methods for their use

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4565696A (en) * 1983-08-03 1986-01-21 The Regents Of The University Of California Production of immunogens by antigen conjugation to liposomes
GB8704171D0 (en) * 1987-02-23 1987-04-01 Clayton Found Res Multivesicular liposomes
US5807572A (en) * 1988-02-18 1998-09-15 Depotech Corporation Multivesicular liposomes having a biologically active substance encapsulated therein in the presence of a hydrochloride
US5422120A (en) 1988-05-30 1995-06-06 Depotech Corporation Heterovesicular liposomes
NZ237464A (en) * 1990-03-21 1995-02-24 Depotech Corp Liposomes with at least two separate chambers encapsulating two separate biologically active substances
US5766627A (en) 1993-11-16 1998-06-16 Depotech Multivescular liposomes with controlled release of encapsulated biologically active substances
NZ276305A (en) 1993-11-16 1997-10-24 Depotech Corp Controlled release vesicle compositions
US5997899A (en) 1996-10-01 1999-12-07 Skyepharma Inc. Method for producing liposomes with increased percent of compound encapsulated
US5891467A (en) * 1997-01-31 1999-04-06 Depotech Corporation Method for utilizing neutral lipids to modify in vivo release from multivesicular liposomes
US6306432B1 (en) * 1997-09-08 2001-10-23 Chiron Corporation High and low load formulations of IGF-I in multivesicular liposomes
EP1028629A4 (en) * 1997-11-05 2003-06-04 Biozone Lab Inc IMPROVED FOOD PREPARATION FOR INFANTS CONTAINING NUTRIENTS AND ACTIVE SUBSTANCES ENCLOSED IN LIPOSOMES
ATE554748T1 (de) * 1997-11-14 2012-05-15 Pacira Pharmaceuticals Inc Herstellung von multivesikulären liposomen
NZ529808A (en) * 2001-05-02 2007-02-23 Purdue Research Foundation Treatment and diagnosis of macrophage mediated disease
AUPR593101A0 (en) * 2001-06-26 2001-07-19 Council Of The Queensland Institute Of Medical Research, The Cytomegalovirus t cell epitopes
US8043602B2 (en) * 2002-02-07 2011-10-25 Endocyte, Inc. Folate targeted enhanced tumor and folate receptor positive tissue optical imaging technology
US20040176381A1 (en) * 2003-03-06 2004-09-09 Walsh Michael J. Methotrexate compliance packaging
US6921667B2 (en) * 2003-03-07 2005-07-26 Prometheus Laboratories, Inc. Methods for direct detection of individual methotrexate metabolites
AU2005264431B2 (en) * 2004-07-16 2010-08-19 Kyorin Pharmaceutical Co., Ltd. Method of effectively using medicine and method concerning prevention of side effect
AU2005282241B2 (en) 2004-09-08 2011-03-03 Chelsea Therapeutics, Inc. Quinazoline derivatives as metabolically inert antifolate compounds.
US20060116334A1 (en) * 2004-12-01 2006-06-01 Curt Hendrix Folate based composition for treatment of the cardiovascular system
WO2006122414A1 (en) 2005-05-17 2006-11-23 Matregen Corp. Depot for sustained and controlled delivery of methotrexate
JP5175723B2 (ja) * 2005-07-05 2013-04-03 パーデュー・リサーチ・ファウンデーション 単球介在性疾患を治療するための組成物の調製
US20090232731A1 (en) * 2006-05-18 2009-09-17 Martin Funk Cationic Liposomal Preparations for the Treatment of Rheumatoid Arthritis
DE102006033837A1 (de) 2006-07-21 2008-01-31 Medac Gesellschaft für klinische Spezialpräparate m.b.H Konzentrierte Methotrexat-Lösungen
WO2008030818A2 (en) 2006-09-05 2008-03-13 Mebiopharm Co., Ltd. Novel liposome compositions
US20080075807A1 (en) * 2006-09-22 2008-03-27 Baldwin Cheryl J Methods Of Fortifying Foods With Vitamin D And Food Products Thereof
GB2443738A (en) 2006-11-09 2008-05-14 Proprius Pharmaceuticals Inc A sustained release methotrexate composition and methods of use thereof
WO2009029543A1 (en) 2007-08-24 2009-03-05 Aegis Therapeutics, Llc Controlled release formulations
CN101965514A (zh) * 2008-01-03 2011-02-02 艾博特生物技术有限公司 预测化合物在治疗银屑病中的长期功效

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5723147A (en) * 1987-02-23 1998-03-03 Depotech Corporation Multivesicular liposomes having a biologically active substance encapsulated therein in the presence of a hydrochloride
US5759573A (en) * 1993-04-22 1998-06-02 Depotech Corporation Cyclodextrin liposomes encapsulating pharmacologic compounds and methods for their use

Also Published As

Publication number Publication date
IL222683A0 (en) 2012-12-31
US20130183371A1 (en) 2013-07-18
JP2015232049A (ja) 2015-12-24
EP2568962A1 (en) 2013-03-20
CN103002877A (zh) 2013-03-27
US10028911B2 (en) 2018-07-24
JP6263508B2 (ja) 2018-01-17
IL222683B (en) 2018-04-30
WO2011143484A1 (en) 2011-11-17
JP5980775B2 (ja) 2016-08-31
US20130183370A1 (en) 2013-07-18
JP2013526545A (ja) 2013-06-24
US20110280932A1 (en) 2011-11-17
EP2568962B1 (en) 2017-11-29
JP2017071652A (ja) 2017-04-13
EP2568962A4 (en) 2014-06-18
US9770414B2 (en) 2017-09-26

Similar Documents

Publication Publication Date Title
CN103002877B (zh) 作为缓解疾病的抗风湿性药（dmard）和抗癌药剂的甲氨蝶呤的持续释放制剂
US20230088661A1 (en) Inhalable liposomal sustained release composition for use in treating pulmonary diseases
JP5645954B2 (ja) イリノテカン又はその塩酸塩のリポソーム及びその製造方法
CN103370055B (zh) 缓释性脂质体组合物及其制造方法
JP2024095802A (ja) カルベジロール分散系の非経口徐放送達
WO2023183297A1 (en) Ion channel prosthetic compositions comprising lipid-coated crystals of amphotericin b
CN100350912C (zh) 一种新型的聚乙二醇衍生化磷脂包载前列腺素e1的纳米微粒给药系统
CN111789816A (zh) 一种糠酸氟替卡松脂质体混悬液及其制备方法
JP5705978B2 (ja) 溶解度が向上した難溶性トリサイクリック誘導体の薬学的組成物
HK1183229B (en) A sustained release formulation of methotrexate as a disease-modifying antirheumatic drug (dmard) and an anti-cancer agent
HK1183229A (en) A sustained release formulation of methotrexate as a disease-modifying antirheumatic drug (dmard) and an anti-cancer agent
CN114126589A (zh) 脂质体阿霉素制剂、用于制备脂质体阿霉素制剂的方法和脂质体阿霉素制剂作为药物的用途
EP3969002A1 (en) Pharmaceutical composition of a weak acid drug and methods of administration
TWI500430B (zh) 伊立替康或鹽酸伊立替康脂質體及其製備方法
WO2025125241A1 (en) Pharmaceutical composition
HK40043569A (en) Inhalable liposomal sustained release composition for use in treating pulmonary diseases

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1183229

Country of ref document: HK

GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1183229

Country of ref document: HK